Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
- President Region International, Francisco Ballester, to retire as of March 1, 2025, after 34 years of service
- Peter Stenico, currently Global Platform Head Biosimilars and Country President Sandoz Austria, concurrently appointed President Region International and a member of the Sandoz Executive Committee
Basel, February 3, 2025 – Sandoz, the global leader in generic and biosimilar medicines, announced today that Francisco Ballester, President Region International and member of the Sandoz Executive Committee, will retire and step down from the SEC on March 1, 2025. Since 2019, Francisco has been responsible in this role for driving business growth and access for patients in markets outside of North America and Europe, while developing highly diverse talents in the region. He is a member of the Health Management and Policy Advisory Council of the Miami Herbert Business School.
Drawing on a strong bench of internal leaders, Peter Stenico will succeed Francisco. Peter was appointed Global Platform Head, Biosimilars in January 2023 and has led the Sandoz global biosimilar strategy. Previously, Peter held the position of Country Head and General Manager for Sandoz in Germany and was also the former President of the German Generics Association (Pro Generika). Peter joined Sandoz in 2002 and has gained vast biosimilars and generics industry experience through various roles covering strategy, M&A and commercial at global, regional and local levels.
Richard Saynor, Chief Executive Officer of Sandoz, said: “It is not every day we can recognize a colleague who has devoted virtually his entire career to our company. Francisco spent over three decades taking on diverse and increasingly more senior roles at the organization, demonstrating focus, passion, and dedication to the business and our people. I am personally grateful for his many contributions and insights we have worked together on the Sandoz Executive Committee. I wish Francisco all the very best for his retirement.
I am immensely proud of the huge wealth of experience we have at Sandoz. Like Francisco, Peter can look back on a successful career of many decades at Sandoz and he will bring this extensive experience to his new role and to the Sandoz Executive Committee. I welcome him to the team and wish him much success in taking Sandoz Region International to the next level of growth.”
DISCLAIMER
This Media Release contains forward-looking statements, which offer no guarantee with regard to future performance. These statements are made on the basis of management’s views and assumptions regarding future events and business performance at the time the statements are made. They are subject to risks and uncertainties including, but not confined to, future global economic conditions, exchange rates, legal provisions, market conditions, activities by competitors and other factors outside of the control of Sandoz. Should one or more of these risks or uncertainties materialize or should underlying assumptions prove incorrect, actual outcomes may vary materially from those forecasted or expected. Each forward-looking statement speaks only as of the date of the particular statement, and Sandoz undertakes no obligation to publicly update or revise any forward-looking statements, except as required by law.
ABOUT SANDOZ
Sandoz (SIX: SDZ; OTCQX: SDZNY) is the global leader in generic and biosimilar medicines, with a growth strategy driven by its Purpose: pioneering access for patients. More than 20,000 people of 100 nationalities work together to ensure 800 million patient treatments are provided by Sandoz, generating substantial global healthcare savings and an even larger social impact. Its leading portfolio of approximately 1,500 products addresses diseases from the common cold to cancer. Headquartered in Basel, Switzerland, Sandoz traces its heritage back to 1886. Its history of breakthroughs includes Calcium Sandoz in 1929, the world’s first oral penicillin in 1951, and the world’s first biosimilar in 2006. In 2023, Sandoz recorded net sales of USD 9.6 billion.
CONTACTS
Global Media Relations contacts | Investor Relations contacts |
Global.MediaRelations@sandoz.com | Investor.Relations@sandoz.com |
Joerg E. Allgaeuer +49 171 838 4838 |
Craig Marks +44 7818 942 383 |
-
Francisco Ballester to retire; Peter Stenico appointed President Region InternationalAd hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules President Region International, Francisco Ballester, to retire as of March2025-02-03
-
EBC Financial Group 与 Shakti Regeneration Institute 合作助力边缘化社区并推动原住民保护工作赞助西孟加拉邦学校并支持全球环保纪录片,彰显 EBC 对教育和可持续发展的承诺 拉纳加特,印度, Feb. 03, 2025 (GLOBE NEWSWIRE) -- EBC Financial Group (EBC),全球2025-02-03
-
一次探索欧洲风味的旅程:特别感谢中国大陆和台湾热情的欢迎与浓厚的兴趣,这是为期三年的“The European Art of Taste – Fruit and Veg Masterpieces”项目完美收官后最突出的成果。 费拉拉, Feb. 03, 20252025-02-03
-
iCourt携手律协开设近百场专题活动,共探法律科技前沿问题2024年,随着人工智能技术的迅猛发展,法律行业正经历着前所未有的变革。在这一背景下,iCourt作为法律人工智能领域的领军企业,积极行动,走过全国62个城市地区,携手各地律2025-02-03
-
谁说武侠只能看男主?徐克射雕电影里的女性角色杀疯了!武侠,从来不是男性的独角戏,这是《射雕英雄传:侠之大者》教给大家的道理。 2025年春节,《射雕英雄传:侠之大者》正式在大银幕上播出了。精彩的打斗、丰满的人物、绝美2025-02-03